Moleculin Biotech shareholders reject reverse stock split at adjourned annual meeting

Moleculin Biotech, Inc.

Proposal No. 5 (reverse stock split) failed: 13,859,013 For, 5,349,509 Against, 161,035 Abstain.
Only 65.60% of outstanding shares were represented at the reconvened meeting on June 15, 2023.
No broker non-votes on the proposal; the amendment required stockholder approval.
The board’s authority to effect a reverse split before the one-year anniversary was denied.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Moleculin Biotech, Inc. shareholders rejected Reverse stock split proposal (to approve an amendment to the certificate of incorporation to grant the Board authority to effect a reverse stock split) at the 2023-06-15 meeting.

Proposal: reverse split
Outcome: failed
Meeting: 2023-06-15

Exact text from the filing

stockholders did not approve the Reverse Split Proposal.

View on SEC.gov

219 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-017697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.